Active, not recruitingPhase 2NCT05687890

A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease

Studying IgA Nephropathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Biocity Biopharmaceutics Co., Ltd.
Principal Investigator
Jianghua Chen, Prof
Zhejiang University
Intervention
Placebo of SC0062(drug)
Enrollment
255 enrolled
Eligibility
18 years · All sexes
Timeline
20232025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05687890 on ClinicalTrials.gov

Other trials for IgA Nephropathy

Additional recruiting or active studies for the same condition.

See all trials for IgA Nephropathy

← Back to all trials